Vyant Bio (OTCMKTS:VYNT) Trading Up 7.8%

Shares of Vyant Bio, Inc. (OTCMKTS:VYNT) were up 7.8% on Thursday . The stock traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.

Vyant Bio Price Performance

The company has a 50 day moving average price of $0.19 and a two-hundred day moving average price of $0.19. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Vyant Bio

An institutional investor recently raised its position in Vyant Bio stock. Captrust Financial Advisors raised its position in Vyant Bio, Inc. (OTCMKTS:VYNT) by 405,350.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 202,725 shares of the company’s stock after buying an additional 202,675 shares during the period. Captrust Financial Advisors owned about 3.45% of Vyant Bio worth $113,000 at the end of the most recent reporting period.

Vyant Bio Company Profile

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).